Serina Therapeutics advances SER-252 Parkinson’s registrational study to Cohort 2 after safety review

Reuters2026/09/09 11:44

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Serina Therapeutics advanced SER-252 into Cohort 2 of its Phase 1b registrational study in advanced Parkinson’s disease.
Blinded Cohort 1 review supported continued dose escalation, with observations consistent with sustained drug exposure and motor improvement in some patients.
Topline results from the single-ascending-dose portion are expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-26-000054), on September 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Serina Therapeutics advances SER-252 Parkinson’s registrational study to Cohort 2 after safety review

You may also like

Crypto prices